Skip to content

Breast Cancer Exercise Intervention Study

Breast Cancer Exercise Intervention Study (BREXINT)

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05957068
Acronym
BREXINT
Enrollment
2156
Registered
2023-07-24
Start date
2023-07-01
Completion date
2033-05-31
Last updated
2025-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early-stage Breast Cancer, Locally Advanced Breast Cancer

Keywords

BREXINT, Muscular Strength, Cardiorespiratory Fitness, Quality of Life

Brief summary

This is a 24-week exercise programme consisting of aerobic exercise and muscle strength training, 3 sessions per week. The first 9 sessions are supervised by physiotherapists in person, followed by 63 sessions monitored remotely (video) or supervised by trainers at ActiveSG (Sport Singapore) gyms.

Detailed description

This is a multi-centre, randomised controlled study of a 6-month (24-week) exercise programme versus observation in 2156 early stage and locally advanced breast cancer patients who have undergone curative breast surgery, and who have completed (neo)adjuvant chemotherapy (if given) or radiotherapy (if given). Patients are stratified by centre (NCC/SGH, NUH), menopausal status, ER/PR status, body fat/muscle ratio. Cardiorespiratory fitness, muscle strength, level of routine daily physical activity, body fat/muscle ratio are monitored during the study period. Blood is collected at baseline, 8 weeks, 16 weeks, 24 weeks, 52 weeks, then annually for 4 times. Questionnaires are periodically conducted to assess quality of life (QoL). A food diary is kept.

Interventions

BEHAVIORALExercise Programme

Aerobic exercise consists of 20-minute brisk walks or jogs (5-6 km/h) on the treadmill each session, reaching a heart rate corresponding to 50%-70% of the patient's VO2max (VO2max is determined before embarking on the exercise programme). Study participants are expected to aim for 50% VO2max at the start of the exercise programme, and gradually increasing to 70% VO2max in subsequent exercise sessions. Strength training comprises a series of circuit resistance exercises targeting the major muscle groups. Patients will perform 2-4 sets of these exercises each session, 8-10 repetitions per set. Both aerobic exercise and strength training are done in the same session. With warm-up and cool-down, each session is estimated to take up 1 hour.

BEHAVIORALControl

Usual care group.

Sponsors

Singapore Cancer Society
CollaboratorOTHER
Genome Institute of Singapore
CollaboratorOTHER
National University of Singapore
CollaboratorOTHER
Singapore General Hospital
CollaboratorOTHER
National Cancer Centre, Singapore
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Eligible patients will be randomised into 2 groups: exercise (intervention group, N = 1078) and usual care (control group, N = 1078). The exercise intervention group will undergo an aerobic exercise and strength training programme.

Eligibility

Sex/Gender
FEMALE
Age
21 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* Patients with histologically or cytologically proven stage 1, 2, or 3 breast cancer * Patients who have undergone curative breast surgery * Patients who have received (neo)adjuvant chemotherapy (if given) and/or radiotherapy (if given) * Females aged 21 years and older * ≤ 8 weeks from breast surgery, or the last adjuvant chemotherapy or radiotherapy session, whichever is latest.

Exclusion criteria

* Cardiovascular, respiratory, musculoskeletal problems that preclude moderate physical activity. * Major medical problems that are deemed by the investigator to be unsuitable for enrollment.

Design outcomes

Primary

MeasureTime frameDescription
Disease-Free Survival (DFS)Up to 5 years.From the date of randomization to when an event, i.e. relapse, has occurred.

Secondary

MeasureTime frameDescription
Overall Survival (OS)Up to 5 years.From the date of randomization to when an event, i.e. death, has occurred.

Other

MeasureTime frameDescription
Changes in absolute and relative VO2.Week 8, Week 16 and Week 24.Changes in absolute (L/min) and relative VO2 (mL/kg/min) at 8, 16 and 24 weeks from baseline.
Changes in heart rate at rest and during CPET.Week 8, Week 16 and Week 24.Changes in heart rate (HR, beats/min) at rest and during CPET, at 8, 16 and 24 weeks from baseline.
Changes in oxygen pulse (VO2/HR) during CPET.Week 8, Week 16 and Week 24.Changes in oxygen pulse (VO2/HR) during CPET, at 8, 16, and 24 weeks from baseline.
Changes in respiratory exchange ratio (RER) during CPET.Week 8, Week 16 and Week 24.Changes in respiratory exchange ratio (RER, unitless) during CPET, at 8, 16, and 24 weeks from baseline
Changes in weight lifted 10 repetition maximum.Week 0, Week 8, Week 16 and Week 24.Changes in weight lifted 10 repetition maximum (10-RM, Kg) for: a. Chest press; b. Latissimus pull-down; c. 2-arm curl; and d. Leg press.
Changes in absolute fat mass and relative fat mass from baseline.Week 8, Week 16 and Week 24.Changes in absolute fat mass (kg) and relative fat mass (%) at 8, 16, and 24 weeks from baseline.
Changes in absolute lean mass and relative lean mass from baseline.Week 8, Week 16 and Week 24.Changes in absolute lean mass (kg) and relative lean mass (%) at 8, 16, and 24 weeks from baseline.
Changes in absolute and relative bone mineral density (BMD) at 8, 16, and 24 weeks from baseline.Week 8, Week 16 and Week 24.Changes in absolute and relative bone mineral density (BMD, in g/cm\^2) at 8, 16, and 24 weeks from baseline.
Body fat/muscle ratio.Week 0, Week 8, Week 16 and Week 24.Body fat mass (in grams) divided by body muscle mass (in grams).

Countries

Singapore

Contacts

Primary ContactDr Elaine LIM, MD, PhD
elaine.lim.hsuen@singhealth.com.sg+65 64368000
Backup ContactCatherine CELES
catherine.celes@nccs.com.sg

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026